Abstract
We report here a new class of compounds, quinoline derivatives, as potential inhibitors of in vitro bovine serum albumin-methylglyoxal glycation. Among compounds 1-19, compound 14 was found to be the most active analog with IC50 of 282.98 ± 8.4 µM. Compounds 12 (IC50 = 661.78 ± 8.7 µM) and 15 (IC50 = 629.43 ± 7.85 7 µM) were also identified as modest inhibitors, in comparison to the standard inhibitor, rutin (IC50 = 294.50 ± 1.5 µM). When evaluated for antioxidant activity through in vitro DPPH radical scavenging assay, compounds 3 (IC50 = 2.19 ± 0.27 µM), 6 (IC50 = 7.35 ± 2.27 µM), 11 (IC50 = 8.96 ± 0.56 µM), and 12 (IC50 = 10.11 ± 2.03 µM), and 15 (IC50 = 7.01 ± 3.87 µM) were found to be more active than the standard i.e. gallic acid (IC50 = 23.34 ± 0.43 µM). These compounds were also evaluated for cytotoxicity against rat fibroblast cell line (3T3 cell line). All compounds were found to be non-toxic in cellular model. This study identifies quinoline derivatives as a new class of inhibitors of protein glycation in vitro, along with antioxidant and non-toxic nature. These properties make them interesting leads for further studies as potential anti-diabetic agents.
Keywords: Advanced glycation end products (AGEs), antioxidant, diabetes, glycation inhibitors, quinoline, reactive oxygen species.
Medicinal Chemistry
Title:Antiglycation Activity of Quinoline Derivatives- A New Therapeutic Class for the Management of Type 2 Diabetes Complications
Volume: 11 Issue: 1
Author(s): Bilquees Bano, Sanaullah Abbasi, Jalaluddin A. J. Khan, Shafqat Hussain, Saima Rasheed, Shahnaz Perveen, Khalid Mohammed Khan and M. Iqbal Choudhary
Affiliation:
Keywords: Advanced glycation end products (AGEs), antioxidant, diabetes, glycation inhibitors, quinoline, reactive oxygen species.
Abstract: We report here a new class of compounds, quinoline derivatives, as potential inhibitors of in vitro bovine serum albumin-methylglyoxal glycation. Among compounds 1-19, compound 14 was found to be the most active analog with IC50 of 282.98 ± 8.4 µM. Compounds 12 (IC50 = 661.78 ± 8.7 µM) and 15 (IC50 = 629.43 ± 7.85 7 µM) were also identified as modest inhibitors, in comparison to the standard inhibitor, rutin (IC50 = 294.50 ± 1.5 µM). When evaluated for antioxidant activity through in vitro DPPH radical scavenging assay, compounds 3 (IC50 = 2.19 ± 0.27 µM), 6 (IC50 = 7.35 ± 2.27 µM), 11 (IC50 = 8.96 ± 0.56 µM), and 12 (IC50 = 10.11 ± 2.03 µM), and 15 (IC50 = 7.01 ± 3.87 µM) were found to be more active than the standard i.e. gallic acid (IC50 = 23.34 ± 0.43 µM). These compounds were also evaluated for cytotoxicity against rat fibroblast cell line (3T3 cell line). All compounds were found to be non-toxic in cellular model. This study identifies quinoline derivatives as a new class of inhibitors of protein glycation in vitro, along with antioxidant and non-toxic nature. These properties make them interesting leads for further studies as potential anti-diabetic agents.
Export Options
About this article
Cite this article as:
Bano Bilquees, Abbasi Sanaullah, Khan A. J. Jalaluddin, Hussain Shafqat, Rasheed Saima, Perveen Shahnaz, Khan Mohammed Khalid and Choudhary Iqbal M., Antiglycation Activity of Quinoline Derivatives- A New Therapeutic Class for the Management of Type 2 Diabetes Complications, Medicinal Chemistry 2015; 11 (1) . https://dx.doi.org/10.2174/1573406410666140526151254
DOI https://dx.doi.org/10.2174/1573406410666140526151254 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry JNK Signalling: A Possible Target to Prevent Neurodegeneration
Current Pharmaceutical Design Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy
Current Drug Discovery Technologies Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews The Dopaminergic System in Peripheral Blood Lymphocytes: From Physiology to Pharmacology and Potential Applications to Neuropsychiatric Disorders
Current Neuropharmacology Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology 11C-verapamil to Assess P-gp Function in Human Brain During Aging,Depression and Neurodegenerative Disease
Current Topics in Medicinal Chemistry Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine